BEIJING, Feb. 23, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products, today announced that for the year ended December 31, 2011, it received subsidies of RMB177,200 from the Chinese government, led by the Ministry of Science and Technology of China, the Ministry of Finance and the State Administration of Taxation, as a result of the Company's status as a High Technology Enterprise.
According to the China Banking Regulatory Commission Guiding Opinions Number 94, companies with high-tech status are eligible for numerous potential benefits including preferential treatment in obtaining other support from the government, competitive commercial bank loans and subsidies for interest on bank loans.
The Company, which is based in Zhongguancun Science Park Beijing Changping District, has benefitted from favorable tax treatment and subsidies. As a certified high technology enterprise, Dehaier is subject to an enterprise income tax rate of 15% tax rate (compared to China's national 25% tax rate) as long as it continues to be certified.Mr. Ping Chen, Chairman and Chief Executive Officer of Dehaier Medical stated, "As a smaller high technology company, we are pleased with the strong support we have received from the government. We continue to invest the free cash flow from our business into further scientific research and development, and we are committed to constantly improve our products, and in turn, the lives of our patients." About Dehaier Medical Systems Ltd. Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD ( Italy), Welch Allyn ( USA), HEYER ( Germany), Timesco (UK), eVent Medical (US) and JMS ( Japan). Dehaier's technology is based on six patents and five software copyrights; additionally Dehaier has two pending software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn Forward-looking Statements This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular statements about Dehaier's receipt of government subsidies and other support and the likelihood to continue to receive such support in the future. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts